Ajay Major, Founder and President of Pager Publications and Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on LinkedIn:
“At the American Society of Hematology (ASH25) Annual Meeting, we presented our patient-reported time toxicity study of 120 patients with relapsed/refractory FL and DLBCL who were actively receiving bispecific antibody therapies (mosun, glofi, epcor).
Briefly, we found that patients receiving mosun and glofi had significantly fewer all-cause healthcare visits and hours spent on cancer-related care in the past 30 days as compared to epcor.
Read our abstract.
Short thread with more slides/details.
This is one of the first and largest studies of patient-reported time burden with various bispecifics in FL and DLBCL, and provides concrete data for counseling patients as part of shared decision-making.
Many thanks to the whole team for bringing this study to fruition: Esprit Ma, Anthony M., Mazie Tsang, Mengyang Di, Dr. Priyanka Pophali, Sally Werner, Rebecca Bungay, Annie Guerin, Lourenia Cassoli, Pallawi Torka.”
Title: Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)
Authors: Ajay Major, Esprit Ma, Anthony Masaquel, Mazie Tsang, Mengyang Di, Supreet Kaur, Priyanka Pophali, Sally Werner, Rebecca Bungay, Dominick Latremouille-Viau, Annie Guerin, Carolina Reyes, Mei Wu, Lourenia Cassoli, and Pallawi Torka
You can read the Full Abstract in Blood.
More posts featuring Ajay Major.